Article
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
Investigational new drugs - 1 Apr 2022
Tamiya Motohiro, Fujikawa Kei, Suzuki Hidekazu, Yokoyama Toshihide, Uenami Takeshi, Tamiya Akihiro, Sato Yuki, Saito Go, Uchida Junji, Morita Mitsunori, Hirashima Tomonori, Fukuda Yasushi, Kanazu Masaki, Hosoya Kazutaka, Suzuki Takuji, Ueno Kiyonobu, Fujimoto Daichi, Kumagai Toru, Teramukai Satoshi
Abstract excerpt
BACKGROUND AND OBJECTIVE: Osimertinib as first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor (EGFR) mutations remains controversial. Sequential EGFR-tyrosine kinase inhibitor (TKI) might be superior to the first line osimertinib in patients at risk of developing acquired T790M mutations. METHODS: We enrolled consecutive patients with EGFR-mutated (deletion...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.